Comparative study on safety of endoscopic retrograde cholangiopancreatography in patients with cirrhosis

Wu JuShan; Li Lei; Song YanMing; Feng Li; Li Bing

doi:10.3969/j.issn.1001-5256.2014.12.009

Issue 12

Dec. 2014

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2014 > 30(12): 1267-1271

PDF( 1630 KB)

Comparative study on safety of endoscopic retrograde cholangiopancreatography in patients with cirrhosis

DOI: 10.3969/j.issn.1001-5256.2014.12.009

Department of Hepatobiliary Surgery, Beijing You'an Hospital, Capital Medical University

Research funding:

Received Date: 2014-06-11
Published Date: 2014-12-20

Abstract

Abstract

Objective To evaluate the safety of endoscopic retrograde cholangiopancreatography (ERCP) in patients with cirrhosis. Methods A retrospective analysis was performed on the clinical data of 347 patients who were admitted to Beijing You'an Hospital and received ERCP from January 2010 to November 2013. Patients were divided into three groups: patients without liver diseases (n = 258) , patients with chronic hepatitis (n = 40) , and patients with cirrhosis (n = 49) . One-way ANOVA or Kruskal-Wallis H test was performed to compare changes in alanine aminotransferase (ALT) , aspartate transaminase (AST) , albumin (Alb) , total bilirubin (TBil) , white blood cells (WBC) , percentage of neutrophils (NEUT) , and serum amylase between the three groups of patients after ERCP. The incidence rates of complications, including hyperamylasemia, acute pancreatitis, infection, hemorrhage, and perforation, and distribution of disease spectrum diagnosis the changes in liver function and blood amylase after ERCP were analyzed compared between the three groups using chi-square test. Results Patients with cirrhosis had significantly lower levels of serum Alb, ALT, and AST than patients in the other two groups before ERCP (H = 3. 68, P = 0. 028; H = 14. 03, P = 0. 001, and H = 8. 00, P = 0. 018, respectively) . After ERCP, the TBil level was significantly higher in the cirrhosis group than in the other two groups (H = 6. 69, P = 0. 035) . Compared with the serum levels of AST and TBil before ERCP, 44. 9% (22 /49) of patients with cirrhosis had higher levels of AST and TBil 3 days after ERCP, the incidence of which was the highest among all three groups. The percentage of NEUT 1 day after ERCP in patients with cirrhosis was 73. 9% ± 12. 7%, which was similar to that in patients without liver diseases (74. 8% ± 11. 0%) and higher than that in patients with chronic hepatitis; the difference between the three groups was statistically significant (H = 7. 31, P = 0. 026) . Although no significant difference in the percentage of patients who had > 80%NEUT 3 days after ERCP was observed between the three groups, the percentage was the highest in the group of patients with cirrhosis (18. 4%, 9 /258) . The incidence rate of hyperamylasemia 24 hours after ERCP 24 h was significantly higher in patients with cirrhosis (53. 1%) than in patients without liver diseases (31. 8%) or with chronic hepatitis (40. 0%) (χ2= 8. 48, P = 0. 014) . The overall complication rates in patients with cirrhosis (18. 4%) was significantly higher than that in patients without liver diseases (8. 1%) or with chronic hepatitis (7. 5%) (χ2= 26. 73, P < 0. 001) . Conclusion ERCP is a safe and effective therapeutic intervention and well tolerated by patients with cirrhosis. Hyperamylasemia should be closely monitored after ERCP.
- liver cirrhosis,
- cholangiopancreatography, endoscopic retrograde,
- postoperative complications,
- hyperamylasemia

FullText(HTML)

References(19)

References

[1]CHAWLA A, PUTHUMANA L, THULUVATH PJ.Autonomic dysfunction and cholelithiasis in patients with cirrhosis[J].Dig Dis Sci, 2001, 46 (3) :495-498.

[2]CONTE D, BARISANI D, MANDELLI C, et al.Cholelithiasis in cirrhosis:analysis of 500 cases[J].Am J Gastroenterol, 1991, 86 (11) :1629-1632.

[3]HU LH, LIAO Z, GAO R, et al.Comparison of complication and success rates of endoscopic retrograde cholangiopancreatography between 2001 and 2007:a retrospective report from Changhai hospital[J].Chin J Dig Endosc, 2009, 26 (5) :248-252. (in Chinese) 胡良皞, 廖专, 高瑞, 等.长海医院2001年与2007年ERCP成功率和并发症比较研究[J].中华消化内镜杂志, 2009, 26 (5) :248-252.

[4]TESTONI PA.Why the incidence of post-ERCP pancreatitis varies considerably?Factors affecting the diagnosis and the incidence of this complication[J].JOP, 2002, 3 (6) :195-201.

[5]PERMEY P, BERTHIER E, PAGEAUX GP, et al.Are drugs a risk factor of post-ERCP pancreatitis?[J].Gastrointest Endosc, 2003, 58 (5) :696-700.

[6] ZHOU YF, ZAHNG X, ZAHNG XF, et al.ERCP in patients with liver cirrhosis:an analysis of 156 cases[J].Chin J Hepatobiliary Surg, 2009, 15 (9) :647-650. (in Chinese) 周益峰, 张啸, 张筱凤, 等.156例合并肝硬化的胆胰疾患内镜临床分析[J].中华肝胆外科杂志, 2009, 15 (9) :647-650.

[7]YANG GY, TAO Y.Mechanism of hyperamylasemia in patients with liver cirrhosis[J].Int J Lab Med, 1985, 5 (1) :35. (in Chinese) 杨根远, 陶原.肝硬化患者高淀粉酶血症的机理[J].国际检验医学杂志, 1985, 5 (1) :35.

[8] HE Y, YUAN FY.Diagnostic relationship between liver and systemic disease[M].Beijing:People's Military Medical Press, 2002:122-123. (in Chinese) 何云, 袁凤仪.肝脏与全身系统疾病诊断关系[M].北京:人民军医出版社, 2002:122-123.

[9]LI XP, WANG JB, SUN KK.Safety of balloon dilation of the sphincter of Oddi for removal of common bile duct stones in patients with liver cirrhosis[J].Chin J Dig Endosc, 2007, 24 (3) :215-217. (in Chinese) 李小平, 王金波, 孙柯科.Oddi括约肌气囊扩张取石治疗肝硬化合并胆总管结石的安全性探讨[J].中华消化内镜杂志, 2007, 24 (3) :215-217.

[10]CHIJIIWA K, KOZAKI N, NAITO T, et al.Treatment of choice for choledocholithiasis in patients with acute obstructive suppurative cholangitis and liver cirrhosis[J].Am J Surg, 1995, 170 (4) :356-360.

[11]PARK DH, KIM MH, LEE SK, et al.Endoscopic sphincterotomy vs.endoscopic papillary balloon dilation for choledocholithiasis in patients with liver cirrhosis and coagulopathy[J].Gastrointest Endosc, 2004, 60 (2) :180-185.

[12]FERREIRA LE, BARON TH.Post-sphincterotomy bleeding:who, what, when and how[J].Am J Gastroenterol, 2007, 102 (12) :2850-2858.

[13]LI SP, XUE DQ, DU HW, et al.Endoscopic therapy for choledocholithiasis with liver cirrhosis and esophagogastric varices:an analysis of 52 cases[J].World Chin J Dig, 2012, 20 (32) :3154-3158.李素萍, 薛迪强, 杜宏伟, 等.内镜下治疗肝硬化食管胃底静脉曲张并胆总管结石52例[J].世界华人消化杂志, 2012, 20 (32) :3154-3158.

[14]LINGHU EQ, YANG YS, LI ZQ, et al.ERCP for patients with gastroesophageal varices combined with pancreatobiliary diseases[J/CD].Chin J Laparoscopic Surgery:Electronic Edition, 2011, 4 (5) :362-364. (in Chinese) 令狐恩强, 杨云生, 李志群, 等.食管胃静脉曲张患者伴胆胰疾病内镜下治疗的研究[J/CD].中华腔镜外科杂志:电子版, 2011, 4 (5) :362-364.

[15] LOU SM, ZHANG X, ZHANG XF.Comparison of two endoscopic therapies for liver cirrhosis with common bile duct stones[J].Zhejiang Med J, 2009, 31 (9) :1279-1280. (in Chinese) 楼颂梅, 张啸, 张筱凤.肝硬化并胆总管结石两种内镜治疗方案疗效的比较[J].浙江医学, 2009, 31 (9) :1279-1280.

[16]WU ZQ, FAN ZN, WANG M.Value of duodenoscopy in the treatment of biliary and pancreatic diseases complicated with hepatocirrhosis[J].Chin J Mini Invas Surg, 2011, 11 (8) :700-703. (in Chinese) 吴正奇, 范志宁, 王敏.十二指肠镜在治疗胆胰疾病合并肝硬变中的价值[J].中国微创外科杂志, 2011, 11 (8) :700-703.

[17]XU L, WANG F, ZHANG YF, et al.Efficacy of endoscopic sphincterotomy versus laparoscopic common bile duct exploration in treatment of common bile duct stones with liver cirrhosis[J].J Surg Concepts Pract, 2011, 16 (6) :587-588. (in Chinese) 徐琳, 王峰, 张宇飞, 等.内镜下乳头切开与开腹胆道探查治疗胆总管结石合并肝硬化的疗效比较[J].外科理论与实践, 2011, 16 (6) :587-588.

[18]MOREIRA VF, ARRIBAS R, SANROMAN AL, et al.Choledocholithiasis in cirrhotic patients:is endoscopic sphincterotomy the safest choice?[J].Am J Gastroenterol, 1991, 86 (8) :1006-1010.

[19]ZHANG Y, LIU D, MA Q, et al.Factors influencing the prevalence of gallstones in liver cirrhosis[J].J Gastroenterol Hepatol, 2006, 21 (9) :1455-1458.

Relative Articles

[1]	Jiongjiong BI, Yingjie MA. Characteristics of the composition of intestinal flora in cirrhotic patients with malnutrition[J]. Journal of Clinical Hepatology, 2024, 40(1): 83-88. doi: 10.12449/JCH240115
[2]	Nan GENG, Ming KONG, Yu CHEN, Zhongping DUAN. Association between portal hypertension and malnutrition in liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(9): 2205-2209. doi: 10.3969/j.issn.1001-5256.2023.09.026
[3]	Honglin MA, Jing YANG, Qiu JIN, Run LUO, Jiao LENG, Xia WANG. Current status of research on nutritional support in end-stage liver disease[J]. Journal of Clinical Hepatology, 2022, 38(1): 215-219. doi: 10.3969/j.issn.1001-5256.2022.01.038
[4]	Yumei HE, Liping WU, Zhiming WANG, Menghao HAO, Ling HU, Jiazhen LI, Xiaobin SUN. Research progress in nutritional support for liver cirrhosis patients[J]. Journal of Clinical Hepatology, 2022, 38(12): 2846-2849. doi: 10.3969/j.issn.1001-5256.2022.12.031
[5]	Yijun ZHANG, Qian ZHANG, Xinhua LUO. Assessment and clinical management of malnutrition and asthenia in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1646-1649. doi: 10.3969/j.issn.1001-5256.2022.07.035
[6]	Chinese Society of Nutritional Oncology, Chinese Society for Parenteral and Enteral Nutrition. Expert opinion on nutritional treatment for patients with biliary tract tumors[J]. Journal of Clinical Hepatology, 2021, 37(9): 2058-2061. doi: 10.3969/j.issn.1001-5256.2021.09.011
[7]	Bo GAO, Yuzheng ZHUGE. Malnutrition in liver cirrhosis: Benefits from improving portal hypertension[J]. Journal of Clinical Hepatology, 2021, 37(12): 2767-2769. doi: 10.3969/j.issn.1001-5256.2021.12.005
[8]	Dandan JIA, Guiying ZHU, Shiyao LIAO, Hui ZHANG, Hui GUO, Lili YANG, Changmiao WANG. Interpretation of European Society for Clinical Nutrition and Metabolism practical guideline : Clinical nutrition in liver disease (2020)[J]. Journal of Clinical Hepatology, 2021, 37(7): 1553-1557. doi: 10.3969/j.issn.1001-5256.2021.07.015
[9]	Xiaoting SONG, Wentao XU, Yu CHEN, Xingshun QI. An excerpt of malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases[J]. Journal of Clinical Hepatology, 2021, 37(12): 2787-2789. doi: 10.3969/j.issn.1001-5256.2021.12.011
[10]	Huijuan XIAO, Tao HAN. Prevention and treatment of malnutrition, sarcopenia, and osteoporosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 26-30. doi: 10.3969/j.issn.1001-5256.2021.01.006
[11]	Xiao HuiJuan, Qi YuMei, Han Tao. An excerpt of ESPEN guideline on clinical nutrition in liver disease (2019)[J]. Journal of Clinical Hepatology, 2019, 35(5): 968-972. doi: 10.3969/j.issn.1001-5256.2019.05.007
[12]	Ma Bao, Deng Yong, Wang ZhiXin, Wang HaiJiu, Fan HaiNing. A preliminary study of the pathogenesis of malnutrition in patients with hepatic alveolar echinococcosis[J]. Journal of Clinical Hepatology, 2018, 34(1): 204-206. doi: 10.3969/j.issn.1001-5256.2018.01.045
[13]	Zhu BingHua, Zhao ZhangQing, Zhou Yang, Xu LieMing. A nutritional risk screening model for patients with liver cirrhosis established using discriminant analysis[J]. Journal of Clinical Hepatology, 2017, 33(6): 1106-1111. doi: 10.3969/j.issn.1001-5256.2017.06.018
[14]	Zhu Bin, Zou CongCong, Zheng Xin. Malnutrition assessment and nutrition support therapy for end-stage liver disease[J]. Journal of Clinical Hepatology, 2017, 33(9): 1699-1706. doi: 10.3969/j.issn.1001-5256.2017.09.014
[15]	Gan XueMei, Li Wu. Nutrition support therapy for patients with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2016, 32(1): 178-181. doi: 10.3969/j.issn.1001-5256.2016.01.039
[16]	Zhang HuiKai, Meng XiangLin, Li HaiLei, Xu YuLing, Luo HongWei. Current status of malnutrition and its association with prognosis in hospitalized patients with decompensated liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(6): 1100-1103. doi: 10.3969/j.issn.1001-5256.2016.06.015
[17]	Zhang Jian. Correlation between malnutrition and prognosis of hepatitis A in Uygur children[J]. Journal of Clinical Hepatology, 2015, 31(8): 1235-1237. doi: 10.3969/j.issn.1001-5256.2015.08.013
[18]	Zhang Min, Hang Lei, Yuan XiaoJie, Yan HongQing. Observation of dietary intervention on nutritional risk in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(8): 764-767. doi: 10.3969/j.issn.1001-5256.2014.08.016
[19]	Wang MaoRong. Paying attention to nutritional management of hepatic encephalopathy in patients with liver cirrhosis: introduction to ISHEN consensus[J]. Journal of Clinical Hepatology, 2013, 29(9): 649-651. doi: 10.3969/j.issn.1001-5256.2013.09.004

Supplements(0)

Cited By

Cited by

Periodical cited type(6)

1.	严兆兰. 青海地区乙型肝炎肝硬化并发轻微肝性脑病Stroop测试及诱发疾病危险因素调查分析. 中华养生保健. 2024(22): 84-86 .
2.	符健，高艺，林锋，李盼盼. 海口地区轻微肝性脑病PHES标准参考值范围的研究. 海南医学. 2023(13): 1903-1907 .
3.	樊亚楠，纪童童，梁荣月，于岩岩，徐京杭. 肝硬化合并显性肝性脑病危险因素的回顾性分析：一项单中心病例对照研究. 中华肝脏病杂志. 2021(02): 133-136 .
4.	边倩，解新科，寇小妮，李京涛，魏海梁，闫曙光. 通腑降浊汤联合乳果糖治疗热扰心神型肝性脑病临床观察. 山东中医杂志. 2021(06): 577-582 .
5.	覃秀容，陈月桥，石清兰，毛德文. 轻微肝性脑病的中西医研究进展. 中医药导报. 2020(12): 152-156 .
6.	王琳. 疏肝解郁胶囊治疗伴抑郁焦虑的肝性脑病患者的效果. 国际精神病学杂志. 2019(05): 925-928 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2624) PDF downloads(567)

Comparative study on safety of endoscopic retrograde cholangiopancreatography in patients with cirrhosis

DOI: 10.3969/j.issn.1001-5256.2014.12.009